Amgen's biosimilar non-inferior to Remicade in Phase III for RA

Amgen Inc. (NASDAQ:AMGN) said 3 mg/kg ABP 710, a biosimilar of Remicade infliximab, was non-inferior to Remicade on

Read the full 189 word article

User Sign In